Chief Executive Officer Mike Doustdar told investors on Tuesday that Novo Nordisk anticipates a slowdown in growth for its international operations through 2026. The company has already lost market exclusivity for key GLP-1 products in at least five major markets—including the U.K., Canada and Australia—and faces intensifying generic competition. Doustdar indicated that international sales growth may moderate to mid-single digits next year, compared with the low-teens growth seen in 2025, as price pressure and volume shifts weigh on revenue outside the United States.

In a preliminary safety update, the U.S. Food and Drug Administration reported that its review of more than 1,200 adverse-event reports and multiple large clinical outcome studies did not reveal an association between GLP-1 receptor agonist use and suicidal thoughts or actions. The agency noted, however, that report quality was uneven and that the absolute number of events was small in both treatment and control arms. To close remaining data gaps, the FDA has launched a formal meta-analysis across all GLP-1 trials and will mine its Sentinel database of insurance claims and electronic health records for post-marketing signals. Novo Nordisk’s own labeling already carries warnings on mood changes and suicidal ideation.

The January 2026 U.S. rollout of oral semaglutide under the Wegovy brand marked the first FDA-approved daily pill for chronic weight management, supplementing the established weekly injectable format. Analysts estimate the new formulation could capture up to 20% of Novo Nordisk’s U.S. obesity prescriptions by mid-2027. Telehealth partner Ro.co reported a cash-pay list price of roughly $149 per month for the pill, drawing substantial consumer interest. The launch has been credited with a nearly 19% rebound in Novo Nordisk’s share performance over the past month, driven by expectations of broader patient adoption and higher treatment persistence compared with injectable competitors.